摘要
目的通过对灯盏细辛两种主要制剂的分析,探讨灯盏细辛注射液在治疗心脑血管疾病方面的物质基础。方法采用文献分析和HPLC分析的方法。结果灯盏细辛注射液与灯盏花素片有相同的临床用途和截然不同的化学成分;提出了可用于中药疗效物质基础研究的“临床—化学”新研究模式。结论咖啡酰衍生物和灯盏花素都是灯盏细辛注射液治疗心脑血管和眼科疾病的有效成分。
OBJECTIVE To investigate the active compounds of Erigeron breviscapus for curing cadiocerebral disease by analyzing Erigerontis injection and Breviscapine tablet. METHODS Literature - analysis and HPLC analysis were used. RESULTS Erigerontis injection and Breviseapine tablet have completely different constituents but with identical indications. A novel pattern for research on herbal active constituents was developed as Clinic - chemistry model. CONCLUSION Caffeoyl derivate and breviscapine are both active constituents in E. breviscapus for cardiocerebral and optic desease.
出处
《华西药学杂志》
CAS
CSCD
北大核心
2005年第4期298-300,共3页
West China Journal of Pharmaceutical Sciences
基金
国家自然科学基金(批准号:30271581)
关键词
灯盏细辛
灯盏花素
有效成分
临床-化学研究模式
文献分析
HPLC
Erigeron breviscapus
Breviscapine
Active constituents
Clinic-chemistry research pattern
Literature analysis
HPLC
